stockrow
Saturday 7 November 2026
Export GCTK’s income statement to Excel — free account
GlucoTrack, Inc.
GCTK Healthcare Medical Devices
- EPS
- +92.1%
- Free cash flow
- +3.42%
- Total debt
- +777.8%
Quarter to June 2026, against a year earlier
0.30
0.08
−21.05%
Follow GCTK
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 1 | 1 | 0 | 0 | — | — | — | — | — | — | 0 | (30.2%) | — | — | — | — | |
| Gross margin, % | 100.00 | 100.00 | 100.00 | 100.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | (100.0) pt | ||||||
| EBT | (5) | (10) | (7) | (4) | (3) | (4) | (4) | (7) | (23) | (19) | (16) | +15.2% | ||||||
| EBT margin, % | (884.37) | (1,752.13) | (15,437.70) | (1,690.38) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +884.4 pt | ||||||
| Net income | (5) | (10) | (7) | (4) | (3) | (4) | (4) | (7) | (23) | (19) | (16) | +15.2% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.11 | 0.09 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (0.93) | (1.64) | (0.80) | (0.02) | (0.18) | (0.26) | (0.29) | (61,263.13) | (112,928.50) | (936.15) | (300.37) | +115.5% | ||||||
| Cash flow | (0.92) | (0.94) | (0.58) | (0.03) | (0.23) | (0.24) | (0.24) | (65,580.00) | (62,450.00) | (736.23) | (97.07) | +110.2% | ||||||
| Capex | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (520.00) | (4.64) | 0.00 | +91.8% | ||||||
| Free cash flow | (0.93) | (0.94) | (0.58) | (0.03) | (0.24) | (0.24) | (0.24) | (65,580.00) | (62,970.00) | (740.87) | (97.07) | +110.0% | ||||||
| Book value | (1.89) | (2.64) | (0.34) | (0.01) | 0.60 | 0.33 | 0.08 | 31,970.00 | (65,000.00) | 136.62 | (10.42) | n/m | ||||||
| Shares, m | 6 | 6 | 8 | 155 | 15 | 15 | 15 | 0 | 0 | 0 | 0 | (46.5%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | 0.00 | 0.0 | |||||
| P/S | 27,686,110.20 | 24,952,324.40 | 9,303,494.32 | 522,885,375.00 | — | — | — | — | — | — | 0.24 | 146,206,826.0 | ||||||
| P/B | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | 0.00 | 0.0 | ||||||
| EV/Sales | 27,686,110.27 | 24,952,324.66 | 9,303,494.51 | 522,885,374.04 | — | — | — | — | — | — | 4.16 | 146,206,825.9 | ||||||
| EV/FCF | (3,142,517.13) | (2,486,583.85) | (1,002,969.78) | (27,730,789.85) | — | — | — | — | — | — | (0.05) | (8,590,715.2) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (5) | (6) | (5) | (4) | (4) | (4) | (4) | (7) | (12) | (15) | (16) | +12.4% | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 | 0 | +2.6% | ||||||
| Free cash flow | (5) | (6) | (5) | (4) | (4) | (4) | (4) | (7) | (13) | (15) | (16) | +12.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 0 | (2) | (3) | (2) | 9 | 5 | 1 | 3 | 4 | 3 | (2) | n/m | |||||
| Net debt | 0 | 0 | 0 | 0 | (10) | (6) | (2) | (4) | (5) | (4) | 1 | n/m | ||||||
| Shareholders’ equity | (11) | (17) | (3) | (1) | 9 | 5 | 1 | 3 | (13) | 3 | (2) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (235.53) | (500.21) | (569.80) | (394.13) | (46.08) | (48.21) | (101.92) | (193.30) | (417.03) | (281.60) | (272.48) | (46.1) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | 60.38 | 75.05 | 69.06 | 164.10 | (71.23) | (57.54) | (138.92) | (320.62) | 461.02 | 381.20 | (620.63) | +320.8 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 39 | 29 | 19 | 7 | 11 | 5 | 3 | 6 | 11 | 15 | — | (10.1%) | |||||
| Revenue/emp, $m | 0.02 | 0.02 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2019 · latest quarter Dec 2019 · fundamentals updated 2 Nov 2026
GlucoTrack, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BJDX Bluejay Diagnostics, Inc. | $2.5M | — (loss-making) | — (loss-making) | — | n/m | +20.05% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IVF INVO Fertility, Inc | $2.4M | — (loss-making) | — (loss-making) | +16.73% (above 0%: growing) | n/m | +35.07% (above 0%: growing) | 35.06% | (59.28%) | Compare |
| CODX Co-Diagnostics, Inc. | $2.4M | — (loss-making) | — (loss-making) | +1.96% (above 0%: growing) | n/m | +17.47% (above 0%: growing) | 72.73% | (3,733.17%) | Compare |
| ICCM IceCure Medical Ltd. | $2.4M | — (loss-making) | — (loss-making) | −0.69% (below 0%: shrinking) | n/m | +3.88% (above 0%: growing) | 32.38% | (466.19%) | Compare |
| NUVOQ Holdco Nuvo Group D.G Ltd. | $2.1M | — (loss-making) | — | — | n/m | −1.05% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ADGM Adagio Medical Holdings, Inc. | $1.7M | — (loss-making) | — | −33.50% (below 0%: shrinking) | n/m | −12.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GCTK GlucoTrack, Inc. | $1.7M | — (loss-making) | — (loss-making) | +342.48% (above 0%: growing) | n/m | +3.42% (above 0%: growing) | 0.00% | 0.00% | |
| NXL Nexalin Technology, Inc. | $1.6M | — (loss-making) | — (loss-making) | −82.72% (below 0%: shrinking) | n/m | −97.23% (below 0%: shrinking) | 72.95% | (18,420.49%) | Compare |
| DHAI DIH Holding US, Inc. | $1.6M | — (loss-making) | — | −30.67% (below 0%: shrinking) | n/m | −167.90% (below 0%: shrinking) | 50.33% | (33.62%) | Compare |
| Median of peers | $2.2M | — | — | −15.68% | — | +1.42% | 33.72% | (46.45%) |
Pay and ownership Proxy statement filed 10 August 2026
Ownership
Directors and executive officers, together
5.90%
Erik Emerson
5.60%
RXRR Capital Partners
5.60%
Apimeds Pharmaceuticals US, Inc.
5.40%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement